[HTML][HTML] Review of microbiota gut brain axis and innate immunity in inflammatory and infective diseases

C Yuan, Y He, K Xie, L Feng, S Gao… - Frontiers in Cellular and …, 2023 - frontiersin.org
The microbiota gut brain (MGB) axis has been shown to play a significant role in the
regulation of inflammatory and infective diseases. Exploring the structure and …

[HTML][HTML] CD20+ T cells: an emerging T cell subset in human pathology

AYS Lee - Inflammation Research, 2022 - Springer
Introduction Although CD20 is classically a B cell marker, in the last three decades, dim
expression has been noted on a subset of T cells as well that has been independently …

Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity

K Shinoda, R Li, A Rezk, I Mexhitaj… - Proceedings of the …, 2023 - National Acad Sciences
A small proportion of multiple sclerosis (MS) patients develop new disease activity soon after
starting anti-CD20 therapy. This activity does not recur with further dosing, possibly reflecting …

Nanovaccines fostering tertiary lymphoid structure to attack mimicry nasopharyngeal carcinoma

Z Wen, H Liu, D Qiao, H Chen, L Li, Z Yang, C Zhu… - ACS …, 2023 - ACS Publications
Tertiary lymphoid structures (TLSs) are formed in inflamed tissues, and recent studies
demonstrated that the appearance of TLSs in tumor sites is associated with a good …

Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis

M Etemadifar, H Nouri, M Pitzalis, ML Idda… - Journal of Neurology …, 2022 - jnnp.bmj.com
Studies among people with multiple sclerosis (pwMS) receiving disease-modifying therapies
(DMTs) have provided adequate evidence for an appraisal of COVID-19 vaccination policies …

[HTML][HTML] Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis

C Rodriguez-Mogeda, ZYGJ van Lierop… - Journal of …, 2023 - Springer
Background Recent studies suggest that extended interval dosing of ocrelizumab, an anti-B
cell therapy, does not affect its clinical effectiveness in most patients with multiple sclerosis …

[HTML][HTML] Potential biological contributers to the sex difference in multiple sclerosis progression

N Alvarez-Sanchez, SE Dunn - Frontiers in Immunology, 2023 - frontiersin.org
Multiple sclerosis (MS) is an immune-mediated disease that targets the myelin sheath of
central nervous system (CNS) neurons leading to axon injury, neuronal death, and …

[HTML][HTML] Bioengineered omental transplant site promotes pancreatic islet allografts survival in non-human primates

H Deng, A Zhang, DRR Pang, Y Xi, Z Yang… - Cell Reports …, 2023 - cell.com
The transplanting islets to the liver approach suffers from an immediate posttransplant loss
of islets of more than 50%, progressive graft dysfunction over time, and precludes recovery …

Trogocytosis and cross-dressing in antigen presentation

P Schriek, JA Villadangos - Current Opinion in Immunology, 2023 - Elsevier
Antigen (Ag)-presenting cells capture or synthesize Ags that are processed into peptides
bound and displayed on the plasma membrane by major histocompatibility complex (MHC) …

[HTML][HTML] Breaching brain barriers: B cell migration in multiple sclerosis

C Rodriguez-Mogeda, S Rodríguez-Lorenzo, J Attia… - Biomolecules, 2022 - mdpi.com
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS)
known for the manifestation of demyelinated lesions throughout the CNS, leading to …